test

Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer

Conditions

Esophagus | Stomach

What is the purpose of this trial?

Determine antitumor activity of AMG 337 in subjects with MET amplified gastric, (G)
gastroesophageal junction (GEJ), or esophageal (E) adenocarcinoma (Cohort 1).


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Amgen, Inc.
Dates:
07/30/2014
Last Updated:
Study HIC#:
1402013465